The flu evolves—an antiviral should, too

Despite the threat of oseltamivir-resistant flu strains reemerging, no new classes of antiviral drugs for the flu have been approved by the FDA in the last 20 years, until now. 5,13-14

In April 2009, oseltamivir-sensitive pandemic H1N1 replaced the previously circulating resistant H1N1 strain.

XOFLUZA has broad-spectrum activity against influenza A and B viruses*, including oseltamivir-resistant strains. 1
A/H1N1, A/H3N2, and influenza B viruses are expected to be the major circulating strains during the 2018-2019 flu season. 15

Consider available information on influenza virus types or subtypes and on drug susceptibility patterns for circulating influenza virus strains when deciding whether to use XOFLUZA.


*The number of subjects who received XOFLUZA at the recommended dose and who were infected with influenza type B virus was limited, including 24 subjects in Trial 1 and 38 subjects in Trial 2.

Antiviral activity was determined against laboratory strains and clinical isolates in vitro. The relationship between antiviral activity and clinical response to treatment in humans has not been established.

Stop viral replication

XOFLUZA works differently by targeting the flu at its source to stop viral replication. 1